Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06636123 · ClinicalTrials.gov registry record · Phase 1
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
A Phase 1 study of Castration-resistant Prostate Cancer, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06636123 is a Phase 1 study of Castration-resistant Prostate Cancer that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 30 participants, below the 215-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06636123, a Phase 1 study of Castration-resistant Prostate Cancer, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.
Conditions Studied
Interventions
- DRUG Investigational Agent Administration
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2031-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06636123
The ClinicalTrials.gov registry entry for NCT06636123 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Castration-resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Investigational Agent Administration is the first listed.
NCT06636123 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06636123 about?
NCT06636123 is a clinical study titled "GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy". The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.
What is the current status of trial NCT06636123?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-02-18. Estimated completion is 2031-10-31.
What conditions does trial NCT06636123 study?
This clinical trial studies the following conditions: Castration-resistant Prostate Cancer.
What interventions are being tested in trial NCT06636123?
The interventions under investigation include: Investigational Agent Administration (DRUG).
Who is sponsoring clinical trial NCT06636123?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06636123 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castration-resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
RECRUITING · Phase 1
-
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
COMPLETED · Phase 1
-
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.